314 related articles for article (PubMed ID: 25591514)
1. [The use of stalevo in the treatment of patients with Parkinson's disease].
Kretova AS; Lyubimov AV
Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(10):35-8. PubMed ID: 25591514
[TBL] [Abstract][Full Text] [Related]
2. An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off.
Koller W; Guarnieri M; Hubble J; Rabinowicz AL; Silver D
J Neural Transm (Vienna); 2005 Feb; 112(2):221-30. PubMed ID: 15503197
[TBL] [Abstract][Full Text] [Related]
3. [Stalevo (levodopa/carbidopa/entacapon)--a new generation drug in the treatment of Parkinson's disease].
Fedorova NV; Levin OS; Smolentseva IG; Kulua TK
Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(9):39-46. PubMed ID: 17069061
[TBL] [Abstract][Full Text] [Related]
4. Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment.
Brooks DJ; Agid Y; Eggert K; Widner H; Ostergaard K; Holopainen A;
Eur Neurol; 2005; 53(4):197-202. PubMed ID: 15970632
[TBL] [Abstract][Full Text] [Related]
5. Use of the new levodopa agent Stalevo (levodopa/carbidopa/entacapone) in the treatment of Parkinson's disease in out-patient clinical practice (the START-M open trial).
Boiko AN; Batysheva TT; Minaeva NG; Babina LA; Vdovichenko TV; Zhuravleva EY; Shikhkerimov RK; Malykhina EA; Khozova AA; Zaitsev KA; Kostenko EV
Neurosci Behav Physiol; 2008 Nov; 38(9):933-6. PubMed ID: 18975095
[TBL] [Abstract][Full Text] [Related]
6. [Direct switch from conventional levodopa to stalevo (levodopa/carbidopa/entacapone) improves quality of life in Parkinson's disease: results of an open-label clinical study].
Litvinenko IV; Odinak MM; Mogil'naia VI; Sologub OS; Sakharovskaia AA
Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(1):51-4. PubMed ID: 19156087
[TBL] [Abstract][Full Text] [Related]
7. Conversion from sustained release carbidopa/levodopa to carbidopa/levodopa/entacapone (stalevo) in Parkinson disease patients.
Lyons KE; Pahwa R
Clin Neuropharmacol; 2006; 29(2):73-6. PubMed ID: 16614538
[TBL] [Abstract][Full Text] [Related]
8. [Long term experience with Stalevo in Szeged, Hungary].
Klivényi P; Vécsei L
Ideggyogy Sz; 2009 May; 62(5-6):178-80. PubMed ID: 19579666
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
Kuoppamäki M; Leinonen M; Poewe W
J Neural Transm (Vienna); 2015 Dec; 122(12):1709-14. PubMed ID: 26347184
[TBL] [Abstract][Full Text] [Related]
10. Entacapone/levodopa/carbidopa combination tablet: Stalevo.
Drugs R D; 2003; 4(5):310-1. PubMed ID: 12952501
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacotherapy of motor manifestations in late stages of Parkinson's disease].
Bogdanov RR; Kotov SV; Kunitsyna AN; Turbina LG
Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(11 Pt 1):21-5. PubMed ID: 21183918
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off.
Findley LJ; Lees A; Apajasalo M; Pitkänen A; Turunen H
Curr Med Res Opin; 2005 Jul; 21(7):1005-14. PubMed ID: 16004667
[TBL] [Abstract][Full Text] [Related]
13. [Nocturnal motor symptoms of Parkinson's disease and their treatment with the three-component drug levodopa/carbidopa/entacapone].
Kulua TK; Fedorova NV; Popovkina OA
Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(9 Pt 2):45-50. PubMed ID: 22027607
[TBL] [Abstract][Full Text] [Related]
14. [Influence of levodopa, stalevo on dyskinesia in Parkinson's disease: STRIDE-PD study].
Liashchenko EA; Skripkina NA; Levin OS
Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(7 Pt 2):62-8. PubMed ID: 23994933
[TBL] [Abstract][Full Text] [Related]
15. [The clinical-pharmacoeconomic study of efficacy of stalevo in the treatment of Parkinson's disease with motor fluctuations].
Levin OS; Smolentseva IG; Fedorova NV; Chigir' IP; Dokadina LV; Makhnev SO
Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(7):27-34. PubMed ID: 18833115
[TBL] [Abstract][Full Text] [Related]
16. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
Fung VS; Herawati L; Wan Y; ;
Mov Disord; 2009 Jan; 24(1):25-31. PubMed ID: 18846551
[TBL] [Abstract][Full Text] [Related]
17. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease.
Hauser RA; Panisset M; Abbruzzese G; Mancione L; Dronamraju N; Kakarieka A;
Mov Disord; 2009 Mar; 24(4):541-50. PubMed ID: 19058133
[TBL] [Abstract][Full Text] [Related]
18. [The use of Stalevo in Hungary for patients with Parkinson disease and its effect on the quality of life].
Klivényi P; Vécsei L
Ideggyogy Sz; 2008 Jan; 61(1-2):42-8. PubMed ID: 18372774
[TBL] [Abstract][Full Text] [Related]
19. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
[TBL] [Abstract][Full Text] [Related]
20. Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study.
Eggert K; Skogar O; Amar K; Luotonen L; Kuoppamäki M; Leinonen M; Nissinen H; Oertel W
J Neural Transm (Vienna); 2010 Mar; 117(3):333-42. PubMed ID: 20013007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
